Benefit–risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease (RMD Open, 2025)

(untitled) - Burmester, GR; Mysler, E; Taylor, P; Hall, S; Wick-Urban, B; Garrison, A; Gao, T; Fish, I; Strengholt, S; Fleischmann, R